CORRECTION

Correction: Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms

  • Pei Huang 1, ,
  • Lin-Yuan Zhang 2, ,
  • Yu-Yan Tan , 1, * ,
  • Sheng-Di Chen , 1, 3, *
Expand
  • 1 Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • 2 Department of Neurology, Shanghai General Hospital, Shanghai 200080,China
  • 3 Lab for Translational Research of Neurodegenerative Diseases, Shanghai;Institute for Advanced Immunochemical Studies (SIAIS), Shanghai TechUniversity, Shanghai 201210, China
* Yu-Yan Tan ;
Sheng-Di Chen

Pei Huang and Lin-Yuan Zhang contributed equally to this work

Online published: 2024-11-29

Cite this article

Pei Huang , Lin-Yuan Zhang , Yu-Yan Tan , Sheng-Di Chen . Correction: Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms[J]. Translational Neurodegeneration, 2023 , 12(0) : 23 . DOI: 10.1186/s40035-023-00349-x

Following publication of this article [1], three errors were identified about the reference.

Correction 1:

136. Crocker TF, Brown L, Lam N, Wray F, Knapp P, Forster A. Information provision for stroke survivors and their carers. Cochrane Database Syst Rev. 2021;11:CD001919.

Should be corrected as follows:

136. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet. 2022;399:1618-24.

Correction 2:

Lina and colleagues reported that 51% of patients with VITT present with cerebral venous sinus thrombosis (CVST) (95% CI 36-66%) [188].” should be corrected toPalaiodimou and colleagues reported that 51% of patients with VITT present with cerebral venous sinus thrombosis (CVST) (95% CI 36-66%) [188].”
188. Palaiodimou L, Stefanou MI, Katsanos AH, Aguiar De Sousa D, Coutinho JM, Lagiou P, et al. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis. Neurology. 2021;97:e2136-47.

Correction 3:

“In human induced pluripotent stem cell (iPSC)-derived neurons and astrocytes, Shi and colleagues found that APOE ε4/ε4 genotype induces an increased rate of SARS-CoV-2 infection than the APOE ε3/ε3 genotype. Moreover, APOE4 astrocytes exhibited a more severe response following SARS-CoV-2 infection. This study provides the first insight into a possible APOE-mediated mechanism of COVID-19 vulnerability and severity [211].” should be corrected to “In human induced pluripotent stem cell (iPSC)-derived neurons and astrocytes, Wang and colleagues found that APOE ε4/ε4 genotype induces an increased rate of SARS-CoV-2 infection than the APOE ε3/ε3 genotype. Moreover, APOE4 astrocytes exhibited a more severe response following SARS-CoV-2 infection. This study provides the first insight into a possible APOE-mediated mechanism of COVID-19 vulnerability and severity [211].”
211. Wang C, Zhang M, Garcia G Jr, Tian E, Cui Q, Chen X, et al. ApoE-isoformdependent SARS-CoV-2 neurotropism and cellular response. Cell Stem Cell. 2021;28:331-42.e5.
The original article [1] has been corrected.
1.
Huang P, Zhang LY, Tan YY, et al. Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms. Transl Neurodegener. 2023;12:5. https://doi.org/10.1186/s40035-023-00337-1.

Outlines

/